Parkinson's disease (PD), the most prevalent neurodegenerative movement disorder, is characterized by an agedependent selective loss of dopaminergic (DA) neurons. Although most PD cases are sporadic, more than 20 responsible genes in familial cases were identified recently. Genetic studies using Drosophila models demonstrate that PINK1, a mitochondrial kinase encoded by a PD-linked gene PINK1, is critical for maintaining mitochondrial function and integrity. This suggests that mitochondrial dysfunction is the main cause of PD pathogenesis. Further genetic and cell biological studies revealed that PINK1 recruits Parkin, an E3 ubiquitin ligase encoded by another PD-linked gene parkin, to mitochondria and regulates the mitochondrial remodeling process via the Parkin-mediated ubiquitination of various mitochondrial proteins. PINK1 also directly phosphorylates the mitochondrial proteins Miro and TRAP1, subsequently inhibiting mitochondrial transport and mitochondrial oxidative damage, respectively. Moreover, recent Drosophila genetic analyses demonstrate that the neuroprotective molecules Sir2 and FOXO specifically complement mitochondrial dysfunction and DA neuron loss in PINK1 null mutants, suggesting that Sir2 and FOXO protect mitochondria and DA neurons downstream of PINK1. Collectively, these recent results suggest that PINK1 plays multiple roles in mitochondrial quality control by regulating its mitochondrial, cytosolic, and nuclear targets.
INTRODUCTION
Parkinson's disease (PD), the second most common neurodegenerative disease, is characterized by a severe and specific loss of dopaminergic (DA) neurons in the substantia nigra. PD patients typically exhibit movement disorders, including tremor, rigidity, postural instability, and bradykinesia of the limbs (reviewed in Lang and Lozano, 1998) . PD mainly occurs sporadically but can also occur genetically. After a mutation in alphasynuclein (PARK1) was identified in a few families with PD (Polymeropoulos et al., 1997) , more than 20 PD-associated genes have been discovered. Among them, parkin (PARK2) (Kitada et al., 1998) , PTEN-induced kinase 1 [PINK1 (PARK6)] (Valente et al., 2004) , and DJ-1 (PARK7) (Bonifati et al., 2003) mediate early-onset autosomal recessive parkinsonism (AR-JP). In contrast, alpha-synuclein and leucine-rich repeat kinase 2 [LRRK2 (PARK8)] (Paisan- Ruiz et al., 2004 ) mediate autosomal dominant forms. The cloning and characterization of these PD-associated genes initiated our understanding of the molecular mechanisms of the pathology of familial PD, facilitating the study of the underlying pathological mechanisms of sporadic PD.
After Langston et al. (1983) reported that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a selective inhibitor of mitochondrial complex I, causes chronic parkinsonism in humans, numerous studies have strongly implicated mitochondrial dysfunction as an important cause of PD. Other mitochondrial toxins such as rotenone and paraquat could also induce parkinsonism accompanied by a loss of DA neurons in various animal models (Betarbet et al., 2000; Brooks et al., 1999; Coulom and Birman, 2004) . Moreover, the activity of mitochondrial complex I is reduced in the brain tissues of patients with sporadic PD (Schapira et al., 1990) . These results prompted vigorous investigation of the molecular links between PD pathogenesis and mitochondrial dysfunction, and Drosophila genetic studies have resulted in an outstanding breakthrough on PINK1 (Clark et al., 2006; Park et al., 2006; Yang et al., 2006) .
MITOCHONDRIAL KINASE PINK1 IS CRITICAL FOR MAINTAINING MITOCHONDRIAL INTEGRITY
PINK1 is a cytosolic serine/threonine kinase mainly localized at mitochondria via an N-terminal mitochondrial-targeting sequence (Silvestri et al., 2005; Valente et al., 2004) . Cells isolated from patients with a PINK1 mutation exhibit reduced complex I activity and increased oxidative damage compared with controls (Hoepken et al., 2007) . Moreover, the downregulation of PINK1 expression in mammalian neuron cells increases cell death with complex I-inhibiting neurotoxin treatment, which is reversed by PINK1 overexpression. These findings suggest that PINK1 plays a functional role in the protection of mitochon- Xi et al. (2010) dria and neurons (Deng et al., 2005; Haque et al., 2008; Petit et al., 2005) . On the basis of these cell biological studies, several research groups generated and characterized PINK1 null animal models (Table 1) . Although PINK1 null mice cannot precisely reproduce human PD symptoms, Drosophila PINK1 null mutants generate strikingly similar PD-related phenotypes such as the selective loss of DA neurons and locomotive defects, including flight disability and slow climbing speed (Clark et al., 2006; Park et al., 2006; Yang et al., 2006) . Loss of PINK1 also induces indirect flight muscle degeneration, which may cause defective wing postures and a crushed thorax. Moreover, mitochondrial swelling accompanied by severe reduction in ATP levels and mitochondrial mass was found in the degenerated indirect flight muscles, and defective mitochondria were also observed in the DA neurons of PINK1 null fly mutants (Park et al., 2006) . These data demonstrate that PINK1 is critical for maintaining mitochondrial integrity and that mitochondrial dysfunction is an important cause of PD. Consistently, the overexpression of Buffy, a Drosophila homolog of mitochondrial protein Bcl-2, rescues mitochondrial defects and impaired climbing ability in PINK1 null mutants, confirming the link between mitochondrial dysfunction and the PD-related phenotypes induced by loss of PINK1 (Park et al., 2006) .
PARKIN PROTECTS MITOCHONDRIA DOWNSTREAM OF PINK1
Parkin is an E3 ubiquitin ligase encoded by parkin, the most commonly mutated PD-associated gene (Shimura et al., 2000) . Overexpressed Parkin can ubiquitinate and degrade several cytosolic proteins in mammalian cells (reviewed in Dawson, 2006) . However, further studies did not find a definite link between these putative Parkin target proteins and PD pathogenesis.
The limitations of cell biological studies were unexpectedly resolved by Drosophila genetic studies focusing on parkin. The loss of parkin in Drosophila successfully recapitulated human PD symptoms such as movement disorders and DA neuron degeneration (Cha et al., 2005; Greene et al., 2003; Pesah et al., 2004) . Moreover, L-DOPA substantially rescued the reduced climbing ability of parkin mutants, confirming that Drosophila parkin mutant models accurately simulate human PD patients (Cha et al., 2005) . However, the molecular mechanism underlying these phenotypes could not be determined until Drosophila PINK1 mutants showed remarkably similar PDassociated defects accompanied by mitochondrial dysfunction. In subsequent fly genetic analyses testing whether PINK1 and Parkin are linked in the same pathway, Parkin expression successfully complemented mitochondrial dysfunction and DA neuron loss in PINK1 mutants. However, PINK1 transgenes could not rescue parkin mutant phenotypes (Clark et al., 2006; Park et al., 2006; Yang et al., 2006) . In addition, Exner et al. (2007) report that mammalian Parkin can also ameliorate the defective mitochondrial phenotypes induced by PINK1 deficiency. These data confirm that PINK1 and Parkin act in the same pathway to protect mitochondria and that Parkin functions downstream of PINK1.
The molecular mechanism of the interaction between PINK1 and Parkin was investigated on the basis of their genetic interaction. Using SH-SY5Y neuroblastoma cells and fly mutants, Kim et al. (2008a) demonstrated that PINK1 translocates Parkin to mitochondria in a kinase activity-dependent manner. Additional biochemical analyses show that PINK1 phosphorylates Parkin and promotes its mitochondrial translocalization (Kim et al., 2008a) . Further studies using mitochondrial uncoupling agents such as carbonyl cyanide m-chlorophenylhydrazone (CCCP) suggest that PINK1 selectively translocates Parkin to mitochondria with low membrane potential, confirming the exis- tence of PINK1-dependent Parkin translocation (Matsuda et al., 2010; Narendra et al., 2010a; Vives-Bauza et al., 2010) . Moreover, CCCP treatment also induces the accumulation of PINK1 protein in depolarized mitochondria (Matsuda et al., 2010; Narendra et al., 2010a; Vives-Bauza et al., 2010) . Subsequent studies suggested that mitochondrial depolarization inhibits PINK1 protein degradation induced by mitochondrial protease presenilin-associated rhomboid-like protein (PARL) and promotes the accumulation of full-length PINK1 in the mitochondrial outer membrane to recruit Parkin (Jin et al., 2010) . However, other researchers argue that the mitochondrial proteasemediated processing of PINK1 is critical for its mitochondrial protective function (Deas et al., 2011; Shi et al., 2011) . Therefore, further investigation is needed to fully understand the molecular activation mechanism of PINK1 in mitochondrial protection as well as the roles of both the full-length and cleaved forms of PINK1 in vivo.
PARKIN REMODELS MITOCHONDRIA BY UBQUITINATING ITS MITOCHONDRIAL TARGETS
In addition to locomotive disorder and DA neuron degeneration, Drosophila PINK1 and parkin mutants exhibit complete male sterility (Clark et al., 2006; Greene et al., 2003; Park et al., 2006) . Mitochondrial remodeling processes -especially fusion and fission -play critical roles in Drosophila spermatogenesis. The mitochondria in each spermatid fuse to form a large onionlike structure called a nebenkern. When the spermatid elongates its tail, the nebenkern also elongates and divides into 2 mitochondrial derivatives that resemble leaf blades. Light microscopic observations of fly spermatids reveal that nebenkerns are swollen and fail to properly divide in PINK1 and parkin mutants. These observations indicate that PINK1 and Parkin control mitochondrial fusion -fission processes (Deng et al., 2008) .
Moreover, further genetic analyses using mitochondrial fusionfission regulators demonstrated that PINK1 and parkin mutant phenotypes are successfully rescued by the overexpression of Drp1, a dynamin-related GTPase that promotes mitochondrial fission, or the downeregulation of Opa1 or Marf, which are other dynamin-related GTPases that induce mitochondrial fusion (Deng et al., 2008; Park et al., 2009; Poole et al., 2008; Yang et al., 2008) . These findings suggest that PINK1 and Parkin balance mitochondrial dynamics by promoting mitochondrial fission to properly maintain mitochondrial function. However, cell biological studies using human cells give opposite results. The co-expression of PINK1 and Parkin or expression of mitochondria-targeting Parkin causes mitochondria in human DA neuroblastoma cells to aggregate (Kim et al., 2008a) . Moreover, PINK1 deficiency or point mutations induce mitochondrial fragmentation in immortal or primary human neuronal cells, indicating that PINK1 and Parkin inhibit mitochondrial fission in human neuronal cells (Exner et al., 2007; Kim et al., 2008a) . Recently, several groups reported that the pro-mitochondrial fusion protein Marf and its human homolog, mitofusin (Mfn), are specifically ubiquitinated and degraded by Parkin in both human and Drosophila systems (Gegg et al., 2010; Tanaka et al., 2010; Ziviani et al., 2010) . Therefore, the exact molecular mechanisms underlying these different mitochondrial remodeling patterns are expected to be elucidated soon.
Recent cell biological studies using CCCP suggest that PINK1 and Parkin are involved in another mitochondrial remodeling process: mitophagy, which is autophagy selective for mitochondrial degradation. After CCCP treatment, Parkin specifically accumulates on impaired mitochondria and induces their turnover via autophagosomes. The deletion of autophagyrelated gene 5 (ATG5) or treatment with autophagy inhibitors blocks this mitochondrial degradation, further confirming the Parkin-induced mitophagy (Narendra et al., 2008) . Subsequent studies discovered that PINK1 is selectively translocated to mitochondria damaged by CCCP and activates their degradation via Parkin (Matsuda et al., 2010; Narendra et al., 2010a; Vives-Bauza et al., 2010) . Moreover, in CCCP-treated cells, Parkin promotes the ubiquitination of impaired mitochondria and the expression of dominant-negative ubiquitin mutants prevents subsequent mitochondrial clearance, demonstrating the functional link between Parkin, ubiquitin, and mitophagy (Geisler et al., 2010; Lee et al., 2010; Matsuda et al., 2010) .
It is also reported that Parkin-mediated mitochondrial ubiquitination recruits the ubiquitin-binding autophagic adaptors p62 and HDAC6 to mitochondria and that a deficiency of either inhibits Parkin-dependent mitophagy (Geisler et al., 2010; Lee et al., 2010) . In addition, Geisler et al. (2010) identified voltagedependent anion channel 1 (VDAC1), a channel protein in the mitochondrial outer membrane, as a target for Parkin-mediated ubiquitination and turnover of damaged mitochondria. These data suggest that PINK1 and Parkin induce the ubiquitination of VDAC1 to recruit the autophagic components p62 and HDAC6 for the specific turnover of damaged mitochondria. However, other studies report that p62 and VDAC1 are dispensable for Parkin-induced mitophagy (Narendra et al., 2010b; and that the outer membrane protein degradation caused by the ubiquitin -proteasome system is critical for Parkin-mediated mitophagy (Chan et al., 2011) . We expect that more important details of the molecular mechanism of mitophagy mediated by the PINK1 -Parkin pathway will be revealed soon.
In addition to mitochondrial remodeling, PINK1 and Parkin also regulate mitochondrial trafficking. Wang et al. (2011) identified mitochondrial Rho-like GTPase Miro as a PINK1 substrate. Miro links mitochondria to microtubules by anchoring kinesin heavy chain (KHC) to the mitochondrial surface and regulates mitochondrial transport, both via its binding partner, Milton (Glater et al., 2006) . Interestingly, PINK1 interacts with and phosphorylates Miro upon mitochondrial depolarization. The phosphorylation of Miro induces the Parkin-dependent degradation of Miro and detaches mitochondria from microtubules (Wang et al., 2011) . Consistent with these findings, PINK1 and Parkin can inhibit mitochondrial movement in rat hippocampal and Drosophila axons (Liu et al., 2012; Wang et al., 2011) .
The roles of PINK1 and Parkin in mitochondrial remodeling and trafficking suggest that PINK1 and Parkin repair moderately damaged mitochondria by inducing their fusion to healthy neighbors and remove severely damaged mitochondria by regulating mitochondrial transport and mitophagy.
OTHER MITOCHONDRIAL PARTNERS OF PINK1 IN MITOCHONDRIAL PROTECTION
Several independent proteomics analyses have been performed to elucidate the novel functional partners of PINK1. Pridgeon et al. (2007) report stable complex formation between PINK1 and TNF-receptor-associated protein 1 (TRAP1). TRAP1 is a mitochondrial molecular chaperone also known as heat shock protein 75 (Hsp75) that modulates the permeability transition pore to inhibit mitochondrial-associated cell death (Kang et al., 2007) . In PC12 cells, PINK1 binds and co-localizes with TRAP1 in mitochondria and phosphorylates TRAP1. PINK1 depletion reduces TRAP1 phosphorylation and oxidative stress resistance, suggesting that TRAP1 is a key signaling molecule mediating the PINK1-induced protection against oxidative stress. The same research group also reports mitochondrial protease high temperature requirement A2 (HtrA2/Omi) as a direct binding partner and indirect phosphorylation target of PINK1 (Plun-Favreau et al., 2007) . However, Drosophila genetic studies do not indicate that HtrA2 acts in the same pathway as PINK1 (Yun et al., 2008) . Moreover, the molecular link between PINK1 and TRAP1 awaits further genetic confirmation using animal models. Another proteomics analysis found phosphoglycerate mutase 5 (PGAM5) as a PINK1-binding mitochondrial protein (Imai et al., 2010) . Although PINK1 cannot phosphorylate PGAM5 and PGAM5 cannot regulate PINK1 kinase activity, the loss of PGAM5 rescues PINK1 Drosophila mutants but not parkin mutants. Conversely, PGAM5 overexpression potentiates PINK1 and parkin mutant phenotypes. These data suggest that PGAM5 functions between PINK1 and Parkin or acts downstream of PINK1 parallel to Parkin (Imai et al., 2010) . Another Drosophila genetic analysis shows that DJ-1 overexpression can ameliorate PINK1 mutant phenotypes but cannot rescue parkin phenotypes (Hao et al., 2010) . However, PINK1 or Parkin overexpression rescues the aberrant mitochondrial phenotype in DJ-1-deficient cells, but DJ-1 does not reduce the mitochondrial fragmentation induced by PINK1 deficiency. These findings suggest that DJ-1 acts independent of PINK1 and Parkin (Exner et al., 2007; Irrcher et al., 2010; Thomas et al., 2011) .
SIR2 AND FOXO AS NOVEL PARTNERS OF PINK1
In addition to understanding the physiological functions of PD genes, Drosophila genetic models have been very useful for discovering novel components of the related signaling pathways. Venderova et al. (2009) report the genetic interaction between LRRK2 and PINK1 in Drosophila eyes. Consistently, mutant LRRK2 can activate pathologic JNK signaling via MAPKKs, and Parkin inhibits JNK in an E3 ligase activitydependent manner; these findings imply crosstalk between LRRK2 and PINK1 (Cha et al., 2005; Gloeckner et al., 2009; Hwang et al., 2010) . Another Drosophila genetic analysis revealed that Sir2 knockdown suppresses fly eye phenotypes induced by PINK1 overexpression (Koh et al., 2012) . Sir2 is a nicotine amide dinucleotide (NAD)-dependent protein deacetylase that has a neuroprotective function in animal models (Araki et al., 2004; Kim et al., 2007a; Parker et al., 2005) . Consistent with these data, Sir2 overexpression ameliorates mitochondrial dysfunction and DA neuron loss in PINK1 mutants. Further genetic analyses demonstrate that FOXO transcription factor, which is regulated by Sir2-mediated deacetylation (Brunet et al., 2004; Daitoku et al., 2004; van der Horst et al., 2004) , mediates the Sir2-induced protection of mitochondria and DA neurons, indicating the mitochondrial protective role of the Sir2-FOXO pathway downstream of PINK1 (Koh et al., 2012) . In contrast, Sir2 overexpression does not rescue parkin mutant phenotypes, and Sir2 deletion only inhibits the development of parkin mutants but not PINK1 mutants. Moreover, the mRNA expression of super oxide dismutase 2 (SOD2) and 4E-binding protein (4EBP), the FOXO target genes with mitochondrial protective roles (Kops et al., 2002; Puig et al., 2003; Tain et al., 2009; Zid et al., 2009) , are substantially reduced in PINK1 mutants but are normal in parkin mutants (Koh et al., 2012) , suggesting that Sir2 and FOXO act in mitochondrial protection in parallel with Parkin. Consistently, Sir2 and FOXO mutants exhibit DA neuron degeneration very similar to that of PINK1 mutants. Furthermore, PINK1 deletion induces no further DA neuron loss in Sir2 or FOXO mutants, further supporting the idea that Sir2 and FOXO protect mitochondria and DA neurons downstream of PINK1 and independent of Parkin (Koh et al., 2012) .
Although Sir2 is localized in the nucleus and cytosol, it has profound effects on mitochondrial functioning (Finley and Haigis, 2009) . Determining the genetic link between Sir2 and PINK1 may provide a key for decoding the signaling mechanism between mitochondria and Sir2. Moreover, PINK1 faces the cytoplasm in the outer membrane (Zhou et al., 2008) , and cytosolic PINK1 can protect neurons from MPTP (Haque et al., 2008) . Therefore, PINK1 may directly phosphorylate and activate Sir2 in the cytoplasm. Alternatively, PINK1 may also indirectly regulate Sir2 via its upstream regulators such as active regulator of Sirt1 (AROS) (Kim et al., 2007b) or deleted in breast cancer 1 (DBC1) (Kim et al., 2008b; Zhao et al., 2008) . This crosstalk between PINK1 and the Sir2-FOXO pathway suggests the novel role of PINK1 in inducing the expression of mitochondrial protective genes by transmitting signals to the cytosol and nucleus.
CONCLUSIONS
Mitochondrial dysfunction has been implicated in PD pathogenesis ever since the first PD studies using MPTP-treated animal models. After decades with little success, pioneering fly genetic studies using PINK1 mutants finally established the molecular link between mitochondrial damage and PD pathogenesis. Subsequent genetic and cell biological analyses revealed the various molecular roles of PINK1 in maintaining mitochondrial integrity and function, suggesting PINK1 as the mainstay of mitochondrial protection (Fig. 1) . Further studies on PINK1 and its partners may provide novel therapeutic targets for more effective treatment of AR-JP and possibly other forms of PD.
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